Clin2
NCT06537596Possibly a fitRecruiting

Imaging test for soft tissue sarcoma and other tumors

Soft Tissue SarcomaPDGFR Alpha Positive Solid Tumours

Part of Cancer clinical trials.

This study tests an imaging agent that may help see tumors with a specific protein called PDGFR alpha. It may help doctors better understand your cancer and plan treatment.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
50 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older
  • You have soft tissue sarcoma or certain other tumors
  • You have a tumor that is at least 2 centimeters or seen on a PET scan
  • You are willing to provide a tissue sample (biopsy) from your tumor
  • You have adequate blood counts, liver and kidney function
  • You are not pregnant or breastfeeding

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06894745Recruiting· Phase 1
PET imaging of solid tumors with 89Zr-DFO-starPEG

This early-phase trial tests a new imaging agent called 89Zr-DFO-starPEG that may help doctors see solid tumors more clearly on PET scans. It is a safety and imaging study, not a treatment, and may help find tumors in people with various types of cancer.

San Francisco, California
NCT07664397Not yet recruiting· Phase 1
Imaging study using a new tracer to find cancer

This trial tests a special imaging agent, [89Zr]DFO-YS5, to see if it can help detect and map certain cancers (including malignant peripheral nerve sheath tumors, bladder cancer, and other solid tumors) during PET scans. It may help doctors see cancerous lesions more clearly.

San Francisco, California
NCT06645808Recruiting· Early Phase 1
PET imaging study for various solid tumors

This study uses a special PET scan to see if a new imaging agent can help find and monitor certain solid tumors. It is for people with colon, rectal, sarcoma, breast, lung, head and neck, esophageal, stomach, pancreas, bladder cancers, or glioblastoma who have had standard treatment before surgery.

Groningen, Provincie Groningen
NCT06646952Recruiting
PET imaging of solid tumors with a CD147-targeting probe

This trial tests a special imaging agent (a nanobody probe) that targets a protein called CD147 on tumor cells. If you have a solid tumor like melanoma, liver, colorectal, pancreatic, breast, stomach, or lung cancer, the PET scan may help doctors see your cancer more clearly.

Beijing, Beijing Municipality
NCT06755086Not yet recruiting
New imaging test for solid tumors using TF-antigen

This trial tests a new imaging agent that targets TF-antigen, a molecule found on many solid tumors. The goal is to see if a PET scan can better detect and monitor cancers like lung, breast, or colon cancer.

Beijing, Beijing Municipality
NCT06720298Not yet recruiting
PET imaging study for solid tumors using CD147 targeting peptide probe

This trial tests a new imaging agent that targets a protein called CD147, which is found on many solid tumors. The goal is to see if this agent can help doctors better stage your cancer using a PET/CT scan.

Beijing, Beijing Municipality

Hear when a new Soft Tissue Sarcoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.